Imperial Health is
serving as one of 600 sites for a global cardiovascular outcomes trial to assess
the safety and effectiveness of bempedoic acid, an investigational medicine, on
the occurrence of major cardiovascular events, such as heart attacks or
strokes, in patients with, or at a high risk for, cardiovascular disease. This research is taking place under the
direction of cardiologist Richard Gilmore, MD, with Imperial Health
The CLEAR Outcomes
study, which stands for Cholesterol
Lowering via BEmpedoic Acid-inhibiting Regimen,
is a double-blind, placebo-controlled study Ė meaning neither the participant
nor the investigator will know who is receiving a treatment. This is a common
mechanism employed to prevent bias in research results.
First and foremost,
candidates must have or be at high risk for cardiovascular disease.
Specifically, this research study focuses on patients who are unable to take
statin medications for the lowering of cholesterol due to side effects. Popular
statin medications include Lipitor, Lescol, Livalo, Pravachol, Zocor and their
generic counterparts. Participant qualifications include, but are not limited
to: being at least 18 years of age, having a history of or a high risk for
cardiovascular disease and being statin intolerant, meaning you have not been
able to tolerate two or more statin medications, and other study criteria.
will receive all study medication and study-related care from a dedicated team
of medical staff at no cost, and health insurance is not required to
Patients who think
they may qualify for and are interested in the CLEAR Outcomes study should
contact Imperial Healthís Research Department at (337) 312-8412 or
Health is the regionís largest multi-specialty medical group. For over 25
years, the groupís Research Department has been conducting groundbreaking
research led by members of Imperial Healthís medical staff. To learn more about
Imperial Health, visit www.imperialhealth.com.
Therapeutics, Inc., the lipid management company behind Bempedoic Acid, is an
Ann Arbor, Michigan-based company passionately committed to developing and
commercializing non-statin medications for the lowering of cholesterol. For
more information on Esperion, visit www.esperion.com.